On April 27, 2023, the U.S. Food and Drug Administration (FDA) reported that Teva Pharmaceuticals USA, Inc., issued a voluntary recall of certain lots of fentanyl buccal tablets, a schedule II substance, to the consumer level because safety updates were omitted in the lots’ product insert/medication guide (MG).